Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It is involved in the nanotechnology; biotechnology; and cancer diagnostics businesses. The company develops MagSense, which completed Phase 1 for the treatment of HER2 breast cancers, as well as advancing the research and development programs for prostate and ovarian cancer. It also develops PrecisionMRX, an iron oxide nanoparticle to detect cancer. The company has collaboration with Siemens MRI to support the Phase 2 study of MagSense HER2 imaging agent. Imagion Biosystems Limited was incorporated in 2016 and is based in Melbourne, Australia.
Metrics to compare | IBX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIBXPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.3x | −2.3x | −0.5x | |
PEG Ratio | −0.01 | −0.03 | 0.00 | |
Price/Book | −1.1x | 3.0x | 2.6x | |
Price / LTM Sales | 1.0x | 3.2x | 3.1x | |
Upside (Analyst Target) | - | 161.4% | 47.8% | |
Fair Value Upside | Unlock | 15.0% | 6.9% | Unlock |